{"favorite_id": 3936, "calc_type": "calculator", "dosing": false, "full_title_en": "International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)", "short_title_en": "IPI and R-IPI", "medium_description_en": "Predicts overall and progression-free survival in DLBCL based on risk factors.", "short_description_en": "DLBCL survival.", "before_use": "", "instructions_en": "<p>Note: IPI results are included for historical comparisons only. Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.</p>", "slug": "international-prognostic-index-diffuse-large-b-cell-lymphoma-ipi-r-ipi", "logic_language": "javascript", "md5": "4a7cde9be5aeb166b524414018f70e16", "cmeVersion": "3936.1", "cmeReleaseDate": "2022-10-07 00:00:00+00+00", "cmeEndDate": "2025-10-03 00:00:00+00+00", "cmeLastReviewed": "2022-10-03 00:00:00+00+00", "search_abbreviation_en": ["ipi", "ripi", "r-ipi", "lymphoma", "CA", "dlbcl"], "seo": {"meta_description_en": "The Revised International Prognostic Index (R-IPI) for Diffuse Large B-cell Lymphoma predicts overall and progression free survival based on risk factors.", "keywords_en": "Lymphoma, DLBCL, prognosis, Hodgkin lymphoma, non Hodgkin lymphoma"}, "content": {"reviewer": {"expert_name": []}, "related_resources": {"videos": [], "sdm_tool": [], "teaching": [], "interests": [], "guidelines": [], "mdcalc_rating": {"clinical": "", "evidence": "", "popularity": ""}, "partner_contact": []}, "how_to_use": {"use_case_en": "<p>Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.</p>", "pearls_pitfalls_en": "<ul> <li>The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) estimates 4-year progression-free survival and 4-year overall survival for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma (DLBCL).</li> <li>The R-IPI provides greater discrimination amongst DLBCL patients with differing survival based on easily obtained factors.</li> <li>Does not identify any risk group with 4-year survival &lt;50%; hence, other molecular or genetic markers are being researched to help select the worst-outcome patients for alternative treatment/clinical trials.</li> </ul>", "why_use_en": "<p>Using the same criteria as the older International Prognostic Index (IPI), the revised IPI (R-IPI) discriminates among <em>three</em> different prognostic groups (versus two by IPI), providing more clinical relevance.</p>"}, "next_steps": {"advice_en": "", "management_en": "<p>Patients with poor prognosis should be strongly considered for clinical trial enrollment and tertiary center referral for investigational therapy.</p>", "critical_actions_en": "<p>Correct staging and selecting correct performance status are the most potentially difficult factors.</p>"}, "about": {"formula_en": "<p>Addition of the selected points:</p> <table> <tbody> <tr> <td>&nbsp;</td> <td> <p><strong>0 points</strong></p> </td> <td> <p><strong>1 point</strong></p> </td> </tr> <tr> <td> <p><strong>Age</strong></p> </td> <td> <p><span>\u226460</span></p> </td> <td> <p><span>&gt;60 years</span></p> </td> </tr> <tr> <td> <p><strong>Ann Arbor stage*</strong></p> </td> <td> <p><span>Stage I or II (localized disease)</span></p> </td> <td> <p><span>Stage III or IV (advanced disease)</span></p> </td> </tr> <tr> <td> <p><strong>ECOG performance status</strong></p> </td> <td> <p><span>0 or 1</span></p> </td> <td> <p><span>\u22652</span></p> </td> </tr> <tr> <td> <p><strong>Serum LDH</strong></p> </td> <td> <p><span>\u22641\u00d7 normal</span></p> </td> <td> <p><span>&gt;1\u00d7 normal</span></p> </td> </tr> <tr> <td> <p><strong>Extranodal sites</strong></p> </td> <td> <p><span>\u22641</span></p> </td> <td> <p><span>&gt;1</span></p> </td> </tr> </tbody> </table> <p><strong>*Ann Arbor stages:&nbsp;</strong></p> <table> <tbody> <tr> <td> <p>I</p> </td> <td> <p>Involvement of a single lymph node region or lymphoid structure (e.g. spleen, thymus, Waldeyer\u2019s ring)</p> </td> </tr> <tr> <td> <p>II</p> </td> <td> <p>Involvement of two or more lymph node regions on the same side of the diaphragm</p> </td> </tr> <tr> <td> <p>III</p> </td> <td> <p>Involvement of lymph regions or structures on both sides of the diaphragm</p> </td> </tr> <tr> <td> <p>IV</p> </td> <td> <p>Involvement of extranodal site(s) beyond that designated E (see below)</p> </td> </tr> <tr> <td colspan=\"2\"> <p><strong>For all stages</strong></p> </td> </tr> <tr> <td> <p>A</p> </td> <td> <p>No symptoms</p> </td> </tr> <tr> <td> <p>B</p> </td> <td> <p>Fever (38\u00baC), drenching sweats, weight loss (10% body weight over 6 months)</p> </td> </tr> <tr> <td colspan=\"2\"> <p><strong>For stages I to III</strong></p> </td> </tr> <tr> <td> <p>E</p> </td> <td> <p>Involvement of a single, extranodal site contiguous or proximal to known nodal site</p> </td> </tr> </tbody> </table> <p>&nbsp;</p>", "more_info_en": "<p>Interpretation:<br><br></p> <table> <tbody> <tr> <td colspan=\"2\">&nbsp;</td> <td> <p><strong>Risk group</strong></p> </td> <td> <p><strong>4-year overall survival, %</strong></p> </td> <td> <p><strong>4-year progression-free survival, %</strong></p> </td> </tr> <tr> <td rowspan=\"3\"> <p><strong>R-IPI</strong></p> </td> <td> <p><span>0</span></p> </td> <td> <p><span>Very good</span></p> </td> <td> <p><span>94</span></p> </td> <td> <p><span>94</span></p> </td> </tr> <tr> <td> <p><span>1\u20132</span></p> </td> <td> <p><span>Good</span></p> </td> <td> <p><span>79</span></p> </td> <td> <p><span>80</span></p> </td> </tr> <tr> <td> <p><span>3\u20135</span></p> </td> <td> <p><span>Poor</span></p> </td> <td> <p><span>55</span></p> </td> <td> <p><span>53</span></p> </td> </tr> <tr> <td rowspan=\"4\"> <p><strong>IPI</strong></p> </td> <td> <p><span>0\u20131</span></p> </td> <td> <p><span>Low</span></p> </td> <td> <p><span>82</span></p> </td> <td> <p><span>85</span></p> </td> </tr> <tr> <td> <p><span>2</span></p> </td> <td> <p><span>Low-intermediate</span></p> </td> <td> <p><span>81</span></p> </td> <td> <p><span>80</span></p> </td> </tr> <tr> <td> <p><span>3</span></p> </td> <td> <p><span>High-intermediate</span></p> </td> <td> <p><span>49</span></p> </td> <td> <p><span>57</span></p> </td> </tr> <tr> <td> <p><span>4\u20135</span></p> </td> <td> <p><span>High</span></p> </td> <td> <p><span>59</span></p> </td> <td> <p><span>51</span></p> </td> </tr> </tbody> </table> <p>Note: IPI is listed for historical comparison only.</p>", "evidence_based_medicine_en": "<p>The R-IPI evolved from a retrospective study of 365 patients at least 16 years of age with newly diagnosed DLBCL treated in British Columbia with R-CHOP prior to 2005. There was central pathology review in 95% of cases. Patients were followed for 7\u201364 months after 6\u20138 cycles of R-CHOP. Progression-free survival (PFS) and overall survival (OS) outcomes were calculated using conventional IPI for comparison. Risk factors were then redistributed to create a more meaningful stratification grouping.</p> <p>The utility of the R-IPI has been validated in the following studies:</p> <ul> <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26260224\" target=\"_blank\">El-Galaly et al 2015</a>:</li> <ul> <li>Authors also looked at impact of PET staging, not routinely used during IPI/R-IPI development, for prognosis, and concluded R-IPI showed high accuracy in PET era as well.</li> </ul> <li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26054914\" target=\"_blank\">Olszewski et al 2015</a>:</li> <ul> <li>The R-IPI validated via cancer registry data of 19,511 patients (of 119,942 patient pool). Noted that the IPI and R-IPI account for only 16% of survival variation, suggesting molecular markers be evaluated and incorporated into future prognostic indexes.</li> </ul> <li><a href=\"https://academic.oup.com/annonc/article/21/7/1486/163863/Prognostic-models-for-diffuse-large-B-cell\" target=\"_blank\">Bari et al 2010</a>:</li> <ul> <li>Retrospective study of 831 patients from two Italian registries. Confirmed IPI less useful in rituximab era, and validated use of R-IPI, noting still did poorly in worst prognosis patients.</li> </ul> </ul> <p>The original and validation articles address the lack of recognition of the poorest prognosis patients, and this is an area of active research.</p>", "references_list": {"Validation": [{"text": "El-galaly TC, Villa D, Alzahrani M, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90(11):1041-6.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/26260224 "}, {"text": "Olszewski AJ, Winer ES, Castillo JJ. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015;26(8):1163-72.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/26054914 "}, {"text": "Bari A, Marcheselli L, Sacchi S, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol. 2010;21(7):1486-91.", "href": "https://academic.oup.com/annonc/article/21/7/1486/163863/Prognostic-models-for-diffuse-large-B-cell "}, {"text": "Blay J, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998;92(10):3562-8.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/9808548 "}, {"text": "Fanin R, Silvestri F, Geromin A, et al. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index. Bone Marrow Transplant. 1998;21(3):263-71.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/9489649 "}, {"text": "Foussard C, Desablens B, Sensebe L, et al. Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France. Ann Oncol. 1997;8 Suppl 1:49-52.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/9187429 "}, {"text": "Hermans J, Krol AD, Van groningen K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood. 1995;86(4):1460-3.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/7632953 "}], "Outcomes": [{"text": "", "href": ""}], "Validations": [], "Original/Primary Reference": [{"text": "A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-94.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/8141877"}, {"text": "Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-61.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/17105812 "}], "Other References": [{"text": "Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55(6):368-76.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/16282281 "}], "Clinical Practice Guidelines": [{"text": "", "href": ""}], "Manufacturer Website": [{"text": "", "href": ""}]}}, "creator": [{"qa_en": null, "approved": null, "name": "Dr. Laurie H. Sehn", "creator_info": {"deceased": null, "about_en": "<p>Laurie H. Sehn, MD, is a medical oncologist at the British Columbia Cancer Agency and a clinical associate professor at the University of British Columbia. She is on the Board of Directors and is the director of research fellowships for the Lymphoma Foundation Canada (LFC). Dr. Sehn is an active researcher studying aspects of lymphoid cancers.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-lauris-h-sehn.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Sehn+LH%5BAuthor%5D"}}], "contributor": {"expert_name": [{"description": "<p>Randall (Randy) Pierce is in private practice with Northwest Georgia Oncology Centers in Carrollton, Georgia, where he has been in practice since 1998. After graduating from the University of Georgia in 1988, he attended medical school at the Medical College of Georgia. His internal medicine residency and hematology/oncology training were completed at Wake Forest University/Baptist Medical Center in 1998. Dr. Pierce treats most malignancies and has a special interest in myeloma and lymphoma. He is married, has 3 children, and enjoys playing tennis and deep sea fishing.</p>", "firstName": "Randall", "img": "randall-pierce.jpg", "lastName": "Pierce", "name": "Randall Pierce, MD", "target": "randall-pierce", "signedCOI": true, "hasDisclosure": []}]}}, "input_schema": [{"type": "toggle", "name": "age", "conditionality": "", "optional": false, "default": 0, "label_en": "Age", "show_points": true, "tips_en": "", "options": [{"label": "\u226460 years", "value": 0}, {"label": ">60 years", "value": 1}]}, {"type": "toggle", "name": "aarbor_stage", "conditionality": "", "optional": false, "default": 0, "label_en": "Ann Arbor stage III-IV", "show_points": true, "tips_en": "III: Involvement on both sides of the diaphragm, IV: Involvement of extranodal sites", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "ecog", "conditionality": "", "optional": false, "default": 0, "label_en": "<calculator id='3170'>ECOG performance status</calculator> \u22652", "show_points": true, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "serum", "conditionality": "", "optional": false, "default": 0, "label_en": "Serum <abbr title='Lactate Dehydrogenase'>LDH</abbr> level >1\u00d7 normal", "show_points": true, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "nodal", "conditionality": "", "optional": false, "default": 0, "label_en": " >1 extranodal site", "show_points": true, "tips_en": "Bone marrow, GI tract, liver, lung, <abbr title='Central Nervous System'>CNS</abbr>, skin, testes, Waldeyer\u2019s ring", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}], "chief_complaint_en": ["Lymphadenopathy", "Mass"], "specialty_en": ["Hematology and Oncology", "Palliative Care/Hospice"], "purpose_en": ["Prognosis"], "system_en": ["Hematologic", "Oncologic"], "disease_en": ["Cancer", "Hematologic Malignancy", "Lymphoma"], "related_calcs": [{"calcId": 2320, "short_title_en": "FLIPI for Follicular Lymphoma", "slug": "follicular-lymphoma-international-prognostic-index-flipi"}, {"calcId": 4053, "short_title_en": "MIPI", "slug": "mantle-cell-lymphoma-international-prognostic-index-mipi"}, {"calcId": 2321, "short_title_en": "GELF Criteria for Follicular Lymphoma", "slug": "groupe-detude-des-lymphomes-folliculaires-gelf-criteria"}]}